Quantitative Investment Management LLC Invests $893,000 in Hologic, Inc. $HOLX

Key Points

• Quantitative Investment Management LLC has invested approximately $893,000 in Hologic, acquiring 14,460 shares of the medical equipment provider.
• Hologic reported earnings per share (EPS) of $1.08 for its latest quarter, surpassing expectations and indicating a 1.2% revenue increase year-over-year.
• Analysts have upgraded Hologic's stock price targets, with Royal Bank of Canada increasing their target from $72.00 to $87.00, reflecting a bullish outlook on the company.

Quantitative Investment Management LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 14,460 shares of the medical equipment provider's stock, valued at approximately $893,000.

A number of other institutional investors have also recently made changes to their positions in the company. Jump Financial LLC purchased a new position in Hologic during the first quarter worth approximately $881,000. Allstate Corp lifted its position in Hologic by 97.4% during the first quarter. Allstate Corp now owns 14,086 shares of the medical equipment provider's stock worth $870,000 after buying an additional 6,952 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Hologic by 0.8% during the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock worth $216,973,000 after buying an additional 29,133 shares in the last quarter. Norinchukin Bank The lifted its position in Hologic by 13.1% during the first quarter. Norinchukin Bank The now owns 12,168 shares of the medical equipment provider's stock worth $752,000 after buying an additional 1,408 shares in the last quarter. Finally, Capital Fund Management S.A. raised its position in Hologic by 92.7% in the first quarter. Capital Fund Management S.A. now owns 305,176 shares of the medical equipment provider's stock valued at $18,851,000 after purchasing an additional 146,800 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX stock opened at $68.26 on Monday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $15.18 billion, a PE ratio of 28.32, a P/E/G ratio of 2.48 and a beta of 0.49. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The business's fifty day moving average price is $65.90 and its 200 day moving average price is $62.40.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of a number of research analyst reports. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and lifted their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. UBS Group lifted their target price on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Evercore ISI lifted their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Morgan Stanley lifted their target price on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Finally, Wall Street Zen upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.